Quantum Leap Healthcare Collaborative

The I-SPY Trials

For Patients
Agents & Results

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
Close
Close
Close
Close
I-SPY People
Close
Close
<- Back to All Agents

pembrolizumab

Trade Name:
Keytruda
Company:
Merck
Status:
Graduated
Agent Chaperone(s):
Rita NandaMinetta Liu
Treatment Protocol:
Pembrolizumab is a PD-1 Inhibitor. Pembrolizumab was administered at 200 mg intravenously once every 3 weeks (q3w) with Paclitaxel administered at 80 mg/m2 weekly (q1w) for 12 total weeks. This regimen was followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
November 26, 2015
Date Left I-SPY:
November 5, 2016
No. Participants in Arm:
69
Graduating Subtypes:
HER2-, TN, HR+HER2-
Agent Description:

Pembrolizumab (Keytruda) is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes.

Notes:
Final pCR Probabilities:
Primary Manuscript:
, 
. 
 
: 
, 
. 
abstractpdfdoi link

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareers
© 2018  Quantum Leap Healthcare Collaborative